Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.39 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12583381 | 0.88 | CYP2C9 (0.75) | KCNH2CYP2C9CYP2C19MAP2K1BRAF | |
| SCHEMBL12583187 | 0.87 | KCNH2 (0.61) | KCNH2CYP2C9CYP2C19MAP2K1MAP2K2 | |
| SCHEMBL1972509 | 0.85 | CYP2C9 (0.73) | KCNH2CYP2C9CYP2C19MAP2K1BRAF | |
| SCHEMBL1971572 | 0.84 | CYP2C9 (0.61) | KCNH2CYP2C9CYP2C19MAP2K1BRAF | |
| SCHEMBL1974970 | 0.84 | CYP2C9 (0.56) | KCNH2CYP2C9CYP2C19MAP2K1BRAF | |
| SCHEMBL1971873 | 0.83 | CYP2C9 (0.51) | KCNH2CYP2C9CYP2C19MAP2K1BRAF | |
| SCHEMBL1969030 | 0.83 | KCNH2 (0.52) | KCNH2CYP2C9CYP2C19MAP2K1BRAF | |
| SCHEMBL1969916 | 0.82 | CYP2C9 (0.51) | KCNH2CYP2C9CYP2C19MAP2K1MAP2K2 | |
| SCHEMBL1970770 | 0.81 | CYP2C9 (0.59) | KCNH2CYP2C9CYP2C19MAP2K1BRAF | |
| SCHEMBL1972540 | 0.80 | CYP2C9 (0.49) | KCNH2CYP2C9CYP2C19MAP2K1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293763-B2 | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents | GENENTECH, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293763-B2 | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents | GENENTECH, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2231662-B1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | GENENTECH INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2231662-B1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | GENENTECH INC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100280063-A1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | GENENTECH, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100280063-A1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | GENENTECH, INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2009085980-A1 | 8-ANILIN0IMIDAZ0PYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280063-A1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | MAP3K8, MAPK8, MAP3K1 | KCNH2 1456/4885CYP2C9 1838/4885CYP2C19 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.